Sequent operates with significant regulatory approvals (USFDA, EUGMP, WHO, TGA) and maintains a strong global footprint through its Alivira brand. Recently completed a transformational amalgamation with Viyash Lifesciences (effective December 2025), appointing new leadership focused on API business expansion and long-term sustainability.
Cyborg Score Rationale
Strong market position as India's leading animal health company with global presence and regulatory approvals. Recent strategic amalgamation demonstrates growth ambitions, though company remains relatively small-cap with market cap around ₹9,431 crore. Strong operational foundation but facing competitive animal health market dynamics.
Top Insights
Recently completed NCLT-approved amalgamation with Viyash Lifesciences effective December 2025, significantly strengthening portfolio
Strong regulatory profile with approvals from USFDA, EUGMP, WHO, and TGA enabling global market access
Strategically focusing on API business segment with new leadership under Dr. Haribabu Bodepudi (MD & Group CEO)
Multi-continent manufacturing footprint (7 facilities across India, Spain, Brazil, Turkey) provides supply chain resilience and market diversification
Named Competitors
Veterinary Pharmaceuticals — Global animal health leader with diversified portfolio
Animal Health Products — World's largest animal health company
Veterinary APIs & Formulations — European animal health specialist
Recent Developments
(January 2026) Dr. Haribabu Bodepudi appointed as MD & Group CEO; Ramakant Singani becomes CFO effective January 1, 2026
(December 2025) NCLT approval for Viyash Lifesciences amalgamation; 18.2 crore shares allotted to Viyash shareholders
(December 2025) ₹92.5 crore raised via warrant issuance at ₹181.94 per warrant
Open the full interactive Sequent Scientific Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.